Identify your patient’s lung cancer mutations

Guideline-recommended, blood-based mutation results within 72 hours.

 

 

What is the GeneStrat® test?

  • Delivers guideline-recommended1, blood-based mutation results: EGFR, ALK, ROS1, RET, BRAF, and KRAS
  • Results within 72 hours can reduce treatment delays and expedite clinical trial enrollment
  • Drives treatment strategy and facilitates monitoring
DOWNLOAD OUR TEST RESULT REPORT  

Testing Platform

  • Measures circulating cell-free DNA and RNA using Droplet Digital PCR (ddPCR)
  • Highly sensitive and specific mutation detection
  • Clinically validated
LEARN MORE ABOUT DDPCR TESTING  
THE GENES TESTED IN THE GENESTRAT® TEST ARE COVERED BY MEDICARE AND MANY PRIVATE PAYERS.

Nearly 80% of patients currently do not have mutation results available at their initial oncology consult.
How do we change this paradigm with blood-based testing?

Source: Lim, C., et.al. 2015. Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-Small Cell Lung Cancer. Ann Oncol first published online April 28, 2015

Save time, Save tissue

BLOOD-BASED RESULTS WITHIN 72 HOURS EXPEDITE TIME TO TREATMENT IN AS

LITTLE AS 8 DAYS2 FROM DIAGNOSTIC BIOPSY.

Tissue-based Tumor Mutation Testing: Presentation to Treatment

GeneStrat Tumor Mutation Testing: Presentation to Treatment


Reference: 1. NCCN Guidelines 2. Bowling, et al. J Clin Oncol 36, 2018 (suppl; abstr e18519) 3. Hagemann, et al. Cancer. 2015;121:631-9. 4. Vidaver RM et al. J Oncol Pract 2016 Jun 3;12(6):e643-53

Accurate, actionable gemonic results

Available Mutations Clinical Sensitivity Clinical Specificity Concordance Treatment Implications
EGFR Sensitizing
del19, L858R
95.8% 100% 98.8% May benefit from treatment with afatinib, erlotinib, gefitinib, or osimertinib
EGFR Resistance
T790M
86.7% 100% 96.4% May benefit from osimertinib if previously treated with 1st or 2nd generation EGFR TKIs
EML4-ALK Fusions
1, 2, 3
85.0% 100% 92.0% May benefit from treatment with alectinib, crizotinib, ceritinib, or brigatinib depending on previous therapies
KRAS 
G12C, G12D, G12V
87.9% 100% 96.0% KRAS mutations are associated with poorer prognosis
ROS1* 
CD74, SDC4, SLC34A2, EZR, TPM3
100% May benefit from treatment with crizotinib
RET*
KIF5B, CCDC6, TRIM33
100% May benefit from treatment with cabozantinib or vandetinib
BRAF*
V600E
100% May benefit from dabrafenib + trametinib, vemurafenib, or dabrafenib
GeneStrat
Combined variant results
90.9% 100% 97.0% See implications listed above for each variant
SEE OUR PUBLICATION DATA LIBRARY  

We are committed to supporting your treatment strategies and improving the lives of patient’s with lung cancer.

SAVE TIME. 72-HOUR TURNAROUND.

SAVE TISSUE. ONE SIMPLE BLOOD DRAW.

TWO SIDES OF CANCER. GENOMIC & PROTEOMIC TESTING.

$0 OUT OF POCKET EXPENSE FOR MEDICARE AND MEDICAID PATIENTS.

Interested in ordering a test kit?

CLICK HERE TO MAKE AN ONLINE KIT REQUEST  

 

Get in touch

Contact us